BiomEdit
Amy McMillan has a strong background in scientific research and has held various roles in different companies. Amy started their career as a Postdoctoral Fellow at Cleveland Clinic in 2016 and worked there until 2019. After that, they joined DoseBiome in 2019 as a Mitacs Accelerate Fellow, focusing on microbiology research. Amy then progressed to become a Research Scientist-Microbiology and later a Principal Scientist at DoseBiome until 2021. In 2020, Amy also worked as a Principal Scientist at Dose Biosystems. Most recently, they joined BiomEdit in 2022 as a Sr. Research Scientist.
Amy McMillan has a Bachelor's degree in Microbiology and Immunology from Western University, which they obtained from 2007 to 2011. Following that, they pursued a Doctor of Philosophy (PhD) degree in Microbiology and Immunology at the same university, completing it from 2011 to 2016.
This person is not in any offices
BiomEdit
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.